secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK:        0000879407
Form:       8-K
Filed at:   2024-02-06T23:59:59+00:00
Accession:  0001628280-24-003488
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arrowhead reports Q1 revenue of $3.55M, down 94% YoY; operating loss $136.5M; cuts cash burn by up to $100M
--------------------------------------------------------------------------------

- Revenue $3.55M vs $62.55M YoY; net loss $132.9M ($1.24 EPS) from $41.3M ($0.39 EPS) loss prior year.
- Operating expenses $140.1M (R&D $116.5M, G&A $23.6M); operating loss $136.5M.
- Cuts forward cash burn guidance by up to $100M (~$30M/qtr); completed $450M stock offering.
- Terminated ARO-SOD1 and HZN-457; focuses on cardiometabolic, pulmonary programs; hired interim chief medical scientist.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879407/000162828024003488/0001628280-24-003488-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879407/000162828024003488/arwr-20240206.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-003488

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer